Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasm Metastasis × pyrotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 49 HER2-positive Breast Cancer 11 Carcinoma, Non-Small-Cell Lung 5 Brain Neoplasms 4 HER2 Positive Metastatic Breast Cancer 3 HER2 Positive Breast Cancer 3 Breast Diseases 3 Advanced Breast Cancer 3 Colorectal Neoplasms 2 Breast Cancer Invasive 2 Breast Cancer Female 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solid Tumor 1 Salivary Gland Neoplasms 1 Rare Tumour 1 Rare Tumor 1 Pathologic Complete Response 1 Non-squamous NSCLC 1 Non Small Cell Lung 1 Neoplasm Metastasis 1 Metastatic Breast Cancer in the Brain 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-expressing Advanced Solid Tumors 1 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1 HER2+ Early or Locally Advanced Breast Cancer 1 HER2+ Breast Cancer 1

Interventions

pembrolizumab 128 Gemcitabine 115 Capecitabine 107 Fluorouracil 99 Paclitaxel 98 Bevacizumab 91 Oxaliplatin 89 Nivolumab 84 Leucovorin 81 Docetaxel 77 Radiosurgery 74 Irinotecan 72 Cisplatin 69 Carboplatin 69 Cyclophosphamide 60 Magnetic Resonance Spectroscopy 59 Cetuximab 59 Biopsy 51 Specimen Handling 50 Trastuzumab 46 Radiotherapy 44 Ipilimumab 43 Pemetrexed 38 Everolimus 38 Drug Therapy 38 Albumin-Bound Paclitaxel 36 130-nm albumin-bound paclitaxel 36 Fulvestrant 34 Doxorubicin 34 aldesleukin 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04355858 2022-07-26

MULAN

Fudan University

Phase 2 Unknown

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡